Funding for this research was provided by:
Fonds de Recherche du Québec - Santé (281662)
Article History
Received: 20 October 2020
Accepted: 24 February 2021
First Online: 18 March 2021
Declarations
:
: Not applicable.
: Not applicable.
: The authors report no conflicts of interest pertaining to the submitted work. FG has no competing interests to declare. DM has provided consultation and speaker services for Pfizer, Aimmune, Kaleo, Merck, Covis and Pediapharm, and has been part of an advisory board for Pfizer and Bausch Health. He provides privately-paid OIT. He sits on the editorial board for the Journal of Food Allergy. PB reports personal fees from Novartis, Pfizer, Sanofi, ALK, Bausch Health and Aralez, as well as grants from DBV technologies, Regeneron and Sanofi outside the submitted work.